| Identification | Back Directory | [Name]
PND-1186 (Hydrochloride) | [CAS]
1356154-94-3 | [Synonyms]
CS-1120
PND-1186 HCl
PND-1186 (Hydrochloride)
2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-N-methylbenzamide:hydrochloride | [Molecular Formula]
C25H27ClF3N5O3 | [MOL File]
1356154-94-3.mol | [Molecular Weight]
537.97 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 200 mg/mL (371.77 mM; Need ultrasonic)| | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
Water : 20 mg/mL (37.18 mM; Need ultrasonic) |
| Hazard Information | Back Directory | [Uses]
PND-1186 hydrochloride (VS-4718 hydrochloride) is a potent, highly-specific and reversible inhibitor of FAK with an IC50 of 1.5 nM. PND-1186 hydrochloride selectively promotes tumor cell apoptosis[1]. | [in vivo]
PND-1186 (30 mg/kg or 100 mg/kg; subcutaneously; injected subcutaneously in the neck region) inhibits 4T1 subcutaneous tumor growth by induction of apoptosis[1]. | Animal Model: | BALB/c mice[1] | | Dosage: | 30 mg/kg or 100 mg/kg | | Administration: | Injected (100 μL) subcutaneously in the neck region; every 12 h (twice-daily, b.i.d.) for 5 days. | | Result: | 100 mg/kg treatment significantly reduced final 4T1 tumor weight 2-fold whereas 30 mg/kg treatment slightly reduced final tumor weight but was not significantly different compared to control. |
| [storage]
Store at -20°C | [References]
[1] Tanjoni I, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther. 2010 May 15;9(10):764-77. DOI:10.4161/cbt.9.10.11434 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|